Overview of the Center
The Falk Center for Molecular Therapeutics is a molecular biology-based drug discovery center of excellence within the Department of Biomedical Engineering at Northwestern Engineering, tethered to a biotechnology company, Aptinyx Inc.
There has never been a greater need for the development of new and effective medicines for the treatment of diseases. However, the costs for creating new drugs have skyrocketed and therapies for many diseases are not being developed because the patient population is too small to be profitable. A new organizational model is necessary to translate discoveries with therapeutic potential into clinically useful compounds. The Falk Center for Molecular Therapeutics is such a model.
Our research is organized into three different areas:
DEVELOPING DRUG THERAPIES
Rapastinel was recently purchased by Allergan and has successfully passed through Phase II of human clinical trial for treatment-resistant depression. Interestingly, based on animal study data, Rapastinel appears to have therapeutic potential for neuropathic pain, schizophrenia, and autism.